CRISPR Therapeutics AG
Materials and methods for treatment of hereditary haemochromatosis
Last updated:
Abstract:
Materials and methods for treating a patient with hereditary hemochromatosis (HHC), both ex vivo and in vivo, and materials and methods for modulating the expression, function, or activity of a haemochromatosis (HFE) gene in a cell by genome editing.
Status:
Grant
Type:
Utility
Filling date:
16 Mar 2017
Issue date:
10 Aug 2021